Harrison E F, Zwadyk P, Bequette R J, Hamlow E E, Tavormina P A, Zygmunt W A
Appl Microbiol. 1970 May;19(5):746-50. doi: 10.1128/am.19.5.746-750.1970.
Haloprogin was shown to be a highly effective agent for the treatment of experimentally induced topical mycotic infections in guinea pigs. Its in vitro spectrum of activity also includes yeasts, yeastlike fungi (Candida species), and certain gram-positive bacteria. The in vitro and in vivo antifungal activity of haloprogin against dermatophytes was equal to that observed with tolnaftate. The striking differences between the two agents were the marked antimonilial and selective antibacterial activities shown by haloprogin, contrasted with the negligible activities found with tolnaftate. Addition of serum decreased the in vitro antifungal activity of haloprogin to a greater extent than that of tolnaftate; however, diminished antifungal activity was not observed when haloprogin was applied topically to experimental dermatophytic infections. Based on its broad spectrum of antimicrobial activity, haloprogin may prove to be a superior topical agent in the treatment of dermatophytic and monilial infections in man.
卤普罗近被证明是治疗豚鼠实验性诱发的局部真菌感染的高效药物。其体外活性谱还包括酵母菌、类酵母菌（念珠菌属）和某些革兰氏阳性菌。卤普罗近对皮肤癣菌的体外和体内抗真菌活性与托萘酯相当。这两种药物的显著差异在于卤普罗近表现出明显的抗念珠菌和选择性抗菌活性，而托萘酯的活性可忽略不计。血清的加入比托萘酯更能降低卤普罗近的体外抗真菌活性；然而，当将卤普罗近局部应用于实验性皮肤癣菌感染时，未观察到抗真菌活性降低。基于其广泛的抗菌活性谱，卤普罗近可能被证明是治疗人类皮肤癣菌和念珠菌感染的一种更优的局部用药。
